LLY

1,124.07

+3.99%↑

JNJ

228.07

+2.18%↑

ABBV

224.38

+3.43%↑

UNH

397.32

+4.86%↑

MRK

120.34

+4.56%↑

LLY

1,124.07

+3.99%↑

JNJ

228.07

+2.18%↑

ABBV

224.38

+3.43%↑

UNH

397.32

+4.86%↑

MRK

120.34

+4.56%↑

LLY

1,124.07

+3.99%↑

JNJ

228.07

+2.18%↑

ABBV

224.38

+3.43%↑

UNH

397.32

+4.86%↑

MRK

120.34

+4.56%↑

LLY

1,124.07

+3.99%↑

JNJ

228.07

+2.18%↑

ABBV

224.38

+3.43%↑

UNH

397.32

+4.86%↑

MRK

120.34

+4.56%↑

LLY

1,124.07

+3.99%↑

JNJ

228.07

+2.18%↑

ABBV

224.38

+3.43%↑

UNH

397.32

+4.86%↑

MRK

120.34

+4.56%↑

Home・Listă Acțiuni・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Deschisă

3.55 -2.74

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

3.5300000000000002

Maxim

3.75

Indicatori cheie
By Trading Economics
Venit	-511K -28M
Vânzări	-13M 2.6M
EPS	-0.47
Marjă de profit	-1,077.401
Angajați	141
EBITDA	-455K -29M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+320.56% upside

Dividende
By Dow Jones
Următoarele câștiguri	4 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-5.4M 229M
Deschiderea anterioară	6.29
Închiderea anterioară	3.55

Voyager Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 iun. 2026, 23:22 UTC

Câștiguri

Principalele dinamici ale pieței

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 iun. 2026, 23:09 UTC

Acțiuni populare

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 iun. 2026, 20:51 UTC

Câștiguri

Costco Reports 15% Sales Growth in May

3 iun. 2026, 20:43 UTC

Câștiguri

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 iun. 2026, 23:48 UTC

Market Talk

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 iun. 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 iun. 2026, 23:35 UTC

Market Talk

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 iun. 2026, 23:15 UTC

Market Talk

Câștiguri

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 iun. 2026, 22:08 UTC

Acțiuni populare

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 iun. 2026, 21:54 UTC

Market Talk

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 iun. 2026, 21:18 UTC

Câștiguri

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 iun. 2026, 21:15 UTC

Câștiguri

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 iun. 2026, 21:13 UTC

Câștiguri

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 iun. 2026, 21:13 UTC

Câștiguri

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 iun. 2026, 21:12 UTC

Câștiguri

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 iun. 2026, 21:09 UTC

Câștiguri

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 iun. 2026, 21:03 UTC

Câștiguri

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 iun. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 iun. 2026, 20:43 UTC

Câștiguri

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 iun. 2026, 20:39 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 iun. 2026, 20:37 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 iun. 2026, 20:35 UTC

Câștiguri

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 iun. 2026, 20:21 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 iun. 2026, 20:17 UTC

Câștiguri

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 iun. 2026, 20:17 UTC

Câștiguri

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 iun. 2026, 20:15 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 iun. 2026, 20:15 UTC

Câștiguri

Broadcom 2Q Adj EPS $2.44 >AVGO

3 iun. 2026, 20:15 UTC

Câștiguri

Broadcom 2Q EPS $1.91 >AVGO

3 iun. 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 iun. 2026, 20:15 UTC

Câștiguri

Broadcom 2Q Rev $22.19B >AVGO

Comparație

Modificare preț

Voyager Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

320.56% sus

Prognoză pe 12 luni

Medie 15.14 USD 320.56%

Maxim 25 USD

Minim 8 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruVoyager Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

9 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 9 analiști care au acordat evaluări ale acțiunilor Voyager Therapeutics Inc - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.